SIMM and HealZen Announce Global Licensing Agreement with Johnson & Johnson to Co-Develop Best-in-Class BTK Degrader
HealZen Therapeutics
Innovative Small-Molecule Drug Developer
Johnson & Johnson
Medical Device R&D and Manufacturer
On January 10, 2025, the Shanghai Institute of Materia Medica, Chinese Academy of Sciences ("Shanghai Institute of Materia Medica") and Hangzhou HealZen Therapeutics Co., Ltd. ("HealZen Therapeutics") jointly announced a global licensing agreement with Johnson & Johnson* to develop a potential best-in-class BTK degrader for the treatment of various diseases.
Ye Yang, Deputy Director of the Shanghai Institute of Materia Medica, stated: "Since its founding, the Shanghai Institute of Materia Medica has consistently valued international cooperation in scientific research and new drug development. We believe this significant collaboration with Johnson & Johnson will become a new milestone in our institute's history of international cooperation."
*Legal entity, Janssen Pharmaceutica NV
About Shanghai Institute of Materia Medica
The Shanghai Institute of Materia Medica, Chinese Academy of Sciences, established in 1932, is China's oldest comprehensive institution for innovative drug research. The institute focuses on the frontier areas of international life science development and key scientific issues in drug research, conducting fundamental and applied basic research on innovative drugs while advancing new theories, methods, and technologies. It emphasizes the development of new drugs targeting cancer, cardiovascular and cerebrovascular diseases, neuropsychiatric disorders, metabolic diseases, autoimmune diseases, and infectious diseases, while also strengthening the research and development of modern traditional Chinese medicine.
Contact Shanghai Institute of Materia Medica:
suoban@simm.ac.cn
About HealZen Therapeutics
HealZen Therapeutics is a clinical-stage small molecule innovative drug discovery company driven by innovation technology, committed to addressing unmet clinical needs. The company independently develops targeted protein degradation drugs and an intelligent drug discovery platform, focusing on drug research and development in the fields of oncology, autoimmune diseases, and central nervous system disorders.
Contact HealZen Therapeutics:
info@healzentx.com
SIMM/HealZen Announce Global License and Strategic Collaboration to Advance BTK Degrader
Shanghai, China - January 10, 2025 - Shanghai Institute of Materia Medica, Chinese Academy of Sciences (“SIMM”) and Hangzhou HealZen Therapeutics (“HealZen”), jointly announced today it has entered into a global license agreement with Johnson & Johnson* to develop potential best-in-class BTK degrader for the treatment of multiple diseases.
"Since its establishment, SIMM has always placed great emphasis on international collaboration in scientific research and drug development." stated Yang Ye, Deputy Director of SIMM, “We believe this strategic collaboration will mark a new milestone in our global cooperation history."
*Legal entity, Janssen Pharmaceutica NV
About Shanghai Institute of Materia Medica, Chinese Academy of Sciences
Founded in 1932, SIMM has the longest history as a comprehensive research institution for drug discovery in China. In line with frontiers in life sciences and aiming at solving key scientific problems in drug discovery, SIMM carries out both basic and applied studies and develops new theories, methods and technologies. Research priorities are given to treat major diseases, such as cancer, cardio-cerebrovascular disease, neuropsychiatric disease, metabolic disease, autoimmune disease, and infectious disease. SIMM is also exploring the development of modern Traditional Chinese Medicine.
For more information about SIMM, please visit
http://www.simm.ac.cn/
Contact: suoban@simm.ac.cn
About Hangzhou HealZen Therapeutics Co., Ltd.
HealZen is a leading clinical-stage biotechnology company focused on the discovery and development of novel therapies based on our proprietary technology platform. We are dedicated to develop differentiated novel treatment approaches by targeting previously undruggable proteins for potential treatment of various human disease such as cancer, autoimmune diseases and CNS disorders.
For more information about HealZen, please visit
http://www.healzentx.com/
Contact: info@healzentx.com
Disclaimer: The publication/reposting of this article is solely for the purpose of information dissemination, and does not represent the views of this official account or confirm the authenticity of its content. Any judgment made based on this content will be at your own risk.If there is any infringement, please inform us and we will delete it immediately!
Press and hold to follow this official account
